Newly Launched Centessa Pharmaceuticals Plans $100M Debut On NASDAQ

Loading...
Loading...
  • Just two months after Centessa Pharmaceuticals launched after the merger of 10 private biotech companies, the company has filed a $100 million IPO for listing on NASDAQ.
  • Founded by Medicxi, Centessa in February raised a $250 million Series A round of funding.
  • The Centessa portfolio consists of four clinical-stage programs, including two in late-stage clinical development and more than ten additional programs.
  • Centessa’s most advanced candidate is lixivaptan, under development from one of the combined companies, Palladio Biosciences.
  • Lixivaptan is an oral non-peptide, a new chemical agent that works by selectively suppressing the activity of the hormone vasopressin at the V2 receptor being developed for autosomal dominant polycystic kidney disease.
  • The company has two Phase 2 candidates in its pipeline. SerpinPC for hemophilia A and B works as a specific inhibitor of the anticoagulant protease-activated protein C (APC).
  • Imgatuzumab, a humanized, non-fucosylated, anti-EGFR monoclonal antibody, treats cutaneous squamous cell carcinoma other solid tumor indications.
  • Another Centessa subsidiary, Orexia Therapeutics, is developing oral and intranasal orexin receptor agonists to treat narcolepsy type 1.
  • Centessa filed to sell American Deposit Shares on the Nasdaq under the ticker symbol “CNTA.”
Posted In: BiotechNewsHealth CareFinancingOfferingsIPOsGeneralBriefsHemophilia Ahemophilia B
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...